Recognizing and Treating Alzheimer’s Disease Moving Towards Early Diagnosis and Disease Management - Los Angeles
WebcastFaculty
OVERVIEW
Recognizing and Treating Alzheimer’s Disease Moving Towards Early Diagnosis and Disease Management is organized by Med Learning Group and would be held during Jul 29, 2016 - Jul 29, 2017.
The target audience for this medical event for neurologists, psychiatrists, internal medicine and family medicine practitioners, and other HCPs (NPs, PAs, clinical nurse specialists, etc.), who would like to receive additional training in the assessment and care of patients with cognitive impairment. This CME Conference has been approved with a maximum of 1.0 AMA PRA Category 1 Credits.
Conference Objectives are :
• Describe the pathophysiology of Alzheimer’s disease (AD) and the roles of clinical assessment and biomarkers in the workup of cognitive impairment.
• Recognize the importance of early diagnosis, and identify challenges in obtaining an early and accurate diagnosis of AD versus other causes of cognitive impairment.
• Utilize diagnostic algorithms and tools to assist in the detection of cognitive impairment, and discuss their use in the clinic.
• Review current treatment approaches and investigational therapies for the early stages of AD, their mechanisms of action and clinical updates.
• Discuss the individualization of AD management based on stage, comorbidities, the presence and type of additional symptoms, and other patient-related factors.
• Develop strategies for improving communication with patients with early AD and their caregivers and for referring their families to local and national support structures.
Additional details will be posted as soon as they are available.
The target audience for this medical event for neurologists, psychiatrists, internal medicine and family medicine practitioners, and other HCPs (NPs, PAs, clinical nurse specialists, etc.), who would like to receive additional training in the assessment and care of patients with cognitive impairment. This CME Conference has been approved with a maximum of 1.0 AMA PRA Category 1 Credits.
Conference Objectives are :
• Describe the pathophysiology of Alzheimer’s disease (AD) and the roles of clinical assessment and biomarkers in the workup of cognitive impairment.
• Recognize the importance of early diagnosis, and identify challenges in obtaining an early and accurate diagnosis of AD versus other causes of cognitive impairment.
• Utilize diagnostic algorithms and tools to assist in the detection of cognitive impairment, and discuss their use in the clinic.
• Review current treatment approaches and investigational therapies for the early stages of AD, their mechanisms of action and clinical updates.
• Discuss the individualization of AD management based on stage, comorbidities, the presence and type of additional symptoms, and other patient-related factors.
• Develop strategies for improving communication with patients with early AD and their caregivers and for referring their families to local and national support structures.
Additional details will be posted as soon as they are available.
SPECIALITIES
Neurology
Quick Links